Takeda Unites San Diego Operations At New ‘Biotech-Style’ R&D Center

Takeda

 

In 2005, Japan’s big drug firm Takeda acquired a company in North America for the first time. That company was Syrrx, a private San Diego-based biotech that used X-ray crystallography to help determine the structures of disease-related molecules so drugs could be designed to target them.

Now, 14 years and multiple other acquisitions of North America-based companies later, the company has moved its San Diego employees—many of them staff gained through those various deals—into a new, custom-built R&D center. More than 90 percent of them are researchers. The site is one of three the company has worldwide: Its other research centers are in Boston and in Japan’s Kanagawa, a prefecture about 30 miles south of Tokyo.

The site lead? The former general counsel of Syrrx, David Weitz.

“We’ve transitioned from being a site of discrete origin to being a true melting pot,” Weitz said. “Our lineage is from multiple companies and, additionally, from the world-class talent we’ve drawn in as well.”

Read More